ReviewBiosensors2025
Review of Non-Invasive Imaging Technologies for Cutaneous Melanoma.
Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Advances in the Field of Cutaneous Malignancies: Background and Clinical Management.Journal of clinical medicine · 2026Article
- GPT Fusion: Reasoning-Based Integration of Specialized Convolutional Neural Networks for Melanoma Diagnosis.Research square · 2026Article
- Multimodal skin care system using combined image and impedance-based diagnostics.Scientific reports · 2026Article
- Multispectral Laser-Scanning Photoacoustic Microscopy With SRS-Generated Wavelengths for Skin Chromophore Characterization.Journal of biophotonics · 2026Article
- Evaluating GPT-5 for Melanoma Detection Using Dermoscopic Images.Diagnostics (Basel, Switzerland) · 2025Article
- Congenital and Neonatal Skin Disorders: Histopathological Diagnosis and Syndromic Associations.Cureus · 2025Review
- A Novel Radiology-Adapted Logistic Model for Non-Invasive Risk Stratification of Pigmented Superficial Skin Lesions: A Methodological Pilot Study.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Imaging technologies are constantly being developed to improve not only melanoma diagnosis, but also staging, treatment planning, and disease progression. We start with a description of how melanoma is characterized using histology, and then continue by discussing nearly two dozen different technologies, including systems currently used in medical practice and those in development. For each technology, we describe its method of operation, how it is or would be projected to be most commonly used in diagnosing and managing melanoma, and for systems in current use, we identify at least one current manufacturer. We also provide a table including the biomarkers identified by and main limitations associated with each technology and conclude by offering suggestions on specific characteristics that might best enhance a technology's potential for widespread clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.